APA

McCracken A. N., McMonigle R. J., Tessier J., Fransson R., Perryman M. S., Chen B., Keebaugh A., Selwan E., Barr S. A., Kim S. M., Roy S. G., Liu G., Fallegger D., Sernissi L., Brandt C., Moitessier N., Snider A. J., Clare S., Müschen M., Huwiler A., Kleinman M. T., Hanessian S. & Edinger A. L. (20170901). Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. : Leukemia.

Chicago

McCracken A N, McMonigle R J, Tessier J, Fransson R, Perryman M S, Chen B, Keebaugh A, Selwan E, Barr S A, Kim S M, Roy S G, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider A J, Clare S, Müschen M, Huwiler A, Kleinman M T, Hanessian S and Edinger A L. 20170901. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. : Leukemia.

Harvard

McCracken A. N., McMonigle R. J., Tessier J., Fransson R., Perryman M. S., Chen B., Keebaugh A., Selwan E., Barr S. A., Kim S. M., Roy S. G., Liu G., Fallegger D., Sernissi L., Brandt C., Moitessier N., Snider A. J., Clare S., Müschen M., Huwiler A., Kleinman M. T., Hanessian S. and Edinger A. L. (20170901). Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. : Leukemia.

MLA

McCracken A N, McMonigle R J, Tessier J, Fransson R, Perryman M S, Chen B, Keebaugh A, Selwan E, Barr S A, Kim S M, Roy S G, Liu G, Fallegger D, Sernissi L, Brandt C, Moitessier N, Snider A J, Clare S, Müschen M, Huwiler A, Kleinman M T, Hanessian S and Edinger A L. Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation. : Leukemia. 20170901.